Hot Asian Companies To Invest In Right Now

Asian stocks swung between gains and losses as health care companies rose while materials producers fell. Japanese shares climbed as the yen weakened.

BHP Billiton Ltd., the world�� biggest mining company, fell 1 percent in Sydney as it headed for its lowest close since July 22. Alfresa Holdings Corp. gained 3.7 percent in Tokyo to lead health care stocks higher. Mazda Motor Corp., which gets 30 percent of sales in North America, added 2.9 percent as the yen slid for a third day on optimism the U.S. government will avoid default.

The MSCI Asia Pacific Index rose 0.1 percent to 139.16 as of 10:32 a.m. in Tokyo after falling as much as 0.2 percent. U.S. House Republican and Senate Democratic leaders are open to a short-term increase in the debt limit, said congressional aides of both parties who spoke on condition of anonymity.

��he market obviously is expecting the gridlock to be resolved,��said Donald Williams, Sydney-based chief investment officer at Platypus Asset Management Ltd., which oversees about A$1.6 billion ($1.5 billion). ��ut having said that, I think the market is uncertain until this is resolved, and so we��e got choppy trading conditions ahead for the next week or so.��

Top 5 Gas Utility Companies To Buy Right Now: Enanta Pharmaceuticals Inc (ENTA)

Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The Company is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes-protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase, as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. ABT-450, discovered through its collaboration with AbbVie, is a protease inhibitor that has demonstrated in vitro potency against known resistant HCV mutants.

In Phase I studies, ABT-450 co-administered with ritonavir, a commonly used boosting agent to increase the blood concentrations of many protease inhibitors, was shown to be safe and well tolerated. Co-administration of ABT-450 with ritonavir, which it refers to together as ABT-450/r, has enabled once-daily dosing of ABT-450. Phase II studies have demonstrated the efficacy of ABT-450/r in patients with chronic HCV, and other interferon-free Phase II studies of ABT-450-containing regimens continue. AbbVie is developing a next-generation protease inhibitor discovered within the Enanta-AbbVie collaboration. EDP-239 is the NS5A inhibitor discovered by the Company. The Company also has a program to develop nucleotide inhibitors to HCV NS5B polymerase, which is another DAA mechanism considered to have a barrier to resistance. The Company�� Bicyclolide antibiotic product candidate is EDP-788, which it is developing for use as an intravenous drug in the hospital setting and for oral dosing in the home setting. EDP-788 is a prodrug, which means that it is inactive until it is converted in the body into an active compound. EDP-788 is! a water-soluble molecule which, when administered in preclinical models, is cleanly and rapidly converted into the active compound.

Advisors' Opinion:

• [By George Budwell]

  Normally, such strong efficacy results would be hailed as a major achievement. However, these results are actually less impressive than those by competing drug's developed by AbbVie (NYSE: ABBV  ) , Enanta Pharmaceuticals (NASDAQ: ENTA  ) and Gilead. Bristol-Myers' therapy also has a treatment duration double that of Gilead's drug Sovaldi for genotype 1 patients. So, while these results are impressive in their own right, the therapy's commercial prospects may be limited due to the presence of superior competitors in the market.�

• [By Sean Williams]

  The next big thing in treating hepatitis-C
  The other currently experimental therapy very likely to make it onto the FDA's desk before the midpoint of 2014 is AbbVie's (NYSE: ABBV  ) direct-acting antiviral combo drug. In similar fashion to Sovaldi, this DAA-combo therapy, which includes ABT-450 from Enanta Pharmaceuticals (NASDAQ: ENTA  ) , is running six confirmatory late-stage trials on various genotypes. There are, however, two primary differences between AbbVie's DAA-combo therapy and Sovaldi.

Hot Asian Companies To Invest In Right Now: OncoMed Pharmaceuticals Inc (OMED)

OncoMed Pharmaceuticals, Inc. (OncoMed) incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation; and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company's anti-cancer therapeutics include anti-DLL4 (demcizumab, OMP-21M18), Anti-DLL4/Anti-VEGF Bispecific, and Anti-Notch2/3 (OMP-59R5), Anti-Notch1 (OMP-52M51, Anti-Fzd7, Fzd8-Fc, RSPO-LGR.

Anti-DLL4 (demcizumab, OMP-21M18) is a humanized monoclonal antibody that inhibits Delta Like Ligand 4 (DLL4) in the Notch signaling pathway. The Company has completed a single-agent Phase Ia trial in advanced solid tumor patients. The Company focuses on conducting two Phase Ib combination trials of demcizumab. Anti-DLL4/anti-VEGF bispecific is a monoclonal antibody that targets and inhibits both DLL4 and vascular endothelial growth factor ( VEGF). VEGF is the target of Avastin. Anti-Notch2/3 (OMP-59R5) is a human monoclonal antibody that targets the Notch2 and Notch3 receptors.

Anti-Notch1 OMP-52M51 is a humanized monoclonal antibody targeted to the Notch1 receptor. Anti-Fzd7 OMP-18R5 is a human monoclonal antibody identified by screening against the Frizzled7 receptor (Fzd7) that binds a conserved epitope on five Frizzled receptors and inhibits Wnt signaling. OMP-18R5 is in a Phase I single-agent trial in advanced solid tumor patients. Fzd8-Fc OMP-54F28 is a fusion protein based on a truncated form of the Frizzled8 receptor ( Fzd8). RSPO-LGR ligands signal through the LGR receptor family.

The Company utilizes several robust technologies for the discovery and optimization of its antibody and protein-bas! ed therapeutics, including multiple proprietary technologies. Its antibody technologies include Mammalian Display Technology, Bispecific Antibody Technology, Hybridoma Technology. Mammalian Display Technology utilizes flow cytometry to isolate mammalian cells expressing antibodies on the cell surface with desired characteristics from large libraries of candidate antibodies. Bispecific Antibody Technology is used to generate its anti-DLL4/anti-VEGF antibody. Hybridoma Technology is used for isolating antibodies from mice, including multiplex single-cell screening techniques.

Advisors' Opinion:

• [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]

  The U.S. Food and Drug Administration on Wednesday imposed a partial clinical hold on a second cancer treatment trial by OncoMed Pharmaceuticals Inc.(OMED) The FDA’s action follows a similar hold last Friday on another treatment targeting cancer stem cells.

• [By Roberto Pedone]

  OncoMed Pharmaceuticals (OMED), a clinical development-stage biotechnology company, focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells. This stock closed up 5.3% at $18.08 in Monday's trading session.

  Monday's Volume: 446,000
  
  Three-Month Average Volume: 178,792
  
  Volume % Change: 155%

  From a technical perspective, OMED ripped higher here right above previous support at $16.57 with above-average volume. This stock has been downtrending badly for the last four months and change, with shares moving lower from its high of $28.43 to its recent low of $16.57. During that move, shares of OMED have been making mostly lower highs and lower lows, which is bearish technical price action. That said, shares of OMED have now starting to rebound off some previous support and it's quickly moving within range of triggering a near-term breakout trade. That trade will hit if OMED manages to clear some near-term overhead resistance levels at $19.17 to its 50-day at $19.92 and then above more resistance at $20 with high volume.

  Traders should now look for long-biased trades in OMED as long as it's trending above some key near-term support at $16.57 and then once it sustains a move or close above those breakout levels with volume that hits near or above 178,792 shares. If that breakout kicks off soon, then OMED will set up to re-test or possibly take out its next major overhead resistance levels at $21.80 to $22.43, or even $24 to $24.48.

• [By Lauren Pollock]

  Among the companies with shares expected to actively trade in Tuesday’s session are OncoMed Pharmaceuticals Inc.(OMED), Lexicon Pharmaceuticals Inc.(LXRX) and Krispy Kreme Doughnuts Inc.(KKD)

Hot Asian Companies To Invest In Right Now: Morvest Business Group Ltd (MOR)

Morvest Business Group Limited (Morvest) is a South Africa-based company. The company is an outsourcing and technology services and solutions company. The Company operates in three segments: Business Support Services focuses on consulting professional services and outsourcing services; ICT Solutions focuses on the application implementation and infrastructure services and Retail and Consumer Services, which is engaged in renders management services to the Company. As of May 31, 2012, the Company�� subsidiaries include, Morvest Shared Services (Pty) Limited, Foster Melliar (Pty) Limited, Morvest Human Capital Management (Pty) Limited, Morvest Professional Services (Pty) Limited, ITQ Business Solutions Group (Pty) Limited, Morvest Information Communication and Technology Limited and Morvest Mithratech (Pty) Limited. Advisors' Opinion:

• [By Holly LaFon]

  MorphoSys (MOR) is a German biotechnology company with proprietary technology to develop human antibodies for specific diseases. Over the quarter, the company signed two licensing deals (with GlaxoSmithKline PLC and Celgene Corp., not held by the fund) for its proprietary compounds, providing outside validation for its technology as well as upfront cash and future royalty payments.

Hot Asian Companies To Invest In Right Now: Twitter (TWTR)

Instantly connect to what's most important to you. Follow your friends, experts, favorite celebrities, and breaking news. TechCrunch is a leading technology media property, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking ... Advisors' Opinion:

• [By Matt Jarzemsky]

  Meanwhile, the Global X Social Media Index exchange-traded fund is up 53%. Ad-supported social media businesses have rallied in the second half of the year as Facebook Inc. reported progress selling ads on its mobile app and hype swirled around Twitter Inc.'s(TWTR) $2.1 billion IPO.

• [By Benjamin Pimentel]

  The tech sector also was weighed down by shares of Twitter Inc., (TWTR) �which were down 2.7% to close at $45.73, Intel Corp. (INTC) , which shed 0.4% to close at $25.89 and IBM Corp., (IBM) �which slipped 0.5% to close at $193.55.

Hot Asian Companies To Invest In Right Now: Aon Corporation(AON)

Aon Corporation provides risk management services, insurance and reinsurance brokerage, and human resource consulting and outsourcing services primarily in the United States, the Americas, the United Kingdom, Europe, the Middle East, Africa, and the Asia Pacific. The company?s Risk Solutions segment offers retail brokerage products and services, including affinity products, general underwriting management services, placement services, and captive management services; and advisory services to technology, financial services, agribusiness, aviation, construction, health care, and energy industries, as well as facilitates various risk management solutions for property liability, general liability, professional liability, directors' and officers' liability, workers' compensation, and various healthcare products. This segment also provides risk consulting services comprising captive management; eSolutions products that enable clients to manage risks, policies, claims, and safet y concerns through an integrated technology platform; reinsurance brokerage services, such as actuarial, enterprise risk management, catastrophe management, and rating agency advisory services; property and casualty reinsurance; and specialty lines, which include professional liability, medical malpractice, accident, life, and health, as well as capital management transaction and advisory services. Its HR Solutions segment offers human capital services in the areas of health and benefits, retirement, compensation, and strategic human capital; and benefits administration and human resource business process outsourcing services. The company was founded in 1919 and is headquartered in Chicago, Illinois.

Advisors' Opinion:

• [By Holly LaFon]

  Company Dell Inc. (DELL) Chesapeake Energy (CHK) DirecTV (DTV) Loews (L) Walt Disney (DIS) Aon Plc (AON) The Travelers Companies (TRV) Level 3 Communications (LVLT) FedEx (FDX) Bank of New York Mellon (BK)
  Learn more about Mason and his views on the present economy in his second-quarter letter here. See his portfolio here.

Hot Asian Companies To Invest In Right Now: Equinix Inc.(EQIX)

Equinix, Inc. provides data center services for the protection and connection of information assets to enterprises, financial service companies, and content and network service providers worldwide. It connects businesses with partners and customers through a platform of high performance data centers, containing dynamic ecosystems and the broadest choice of networks. The company operates International Business Exchange (IBX) centers, or IBX data centers, across 38 markets in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. Equinix offers data center services, including premium data center co-location; interconnection and exchange services; network connectivity; business continuity; and outsourced IT infrastructure services. The company connects approximately 4,000 enterprises, cloud, digital content, and financial companies, including 680 network service providers to help them grow their businesses, improve application performance, and protect their vita l digital assets. It markets its products and services through direct sales force and channel marketing program. Equinix was founded in 1998 and is headquartered in Redwood City, California.

Advisors' Opinion:

• [By Holly LaFon]

  Equinix, Inc. (EQIX) is a leading Internet exchange service provider, serving communications, content and enterprise customers in state-of-the-art data centers. Equinix also offers interconnection services to customers seeking to connect directly with other Equinix customers. We believe that this "tethering" of customers in a network neutral environment creates important competitive barriers that distinguish Equinix from other data center business models. Last year, management indicated its intention to convert the company to a REIT. Shares were pressured this quarter, as the market grew concerned about the company's ability to make this REIT conversion. In addition, REIT shares themselves were under pressure on concerns that rising interest rates would depress their relative valuations in the stock market. We believe that Equinix remains an attractive investment, whether or not a REIT conversion eventually occurs.

• [By Tom Taulli]

  Innovation: Innovation is a major priority at AT&T. And so far, it looks like the company is making savvy moves, particularly with its push into the cloud. To this end, AT&T has rolled out NetBond, which involves alliances with top providers like IBM (IBM), Microsoft (MSFT), CSC (CSC) and Equinix (EQIX). But perhaps the most interesting growth initiative is Digital Life, which allows customers to use their smartphones as remote control devices with homes and cars. All in all, the opportunity could be huge, adding another nice revenue stream — AT&T already has agreements with companies like GM (GM), Ford (F), Nissan, Audi, BMW and Tesla (TSLA)